Clicky

Cipher Pharmaceuticals Inc.(CPH)

Description: Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.


Keywords: Medicine Pharmaceutical Pipe Organ Systems Rheumatoid Arthritis Arthritis Pharma Psoriasis Dermatology Skin Ulcer Pipeline Acne Plaque Psoriasis IPO Nail Actinic Keratosis Cutaneous Conditions Keratosis Pharmaceuticals Segment High Cholesterol Onychomycosis Anti Acne Preparations Herpes Labialis Hyperkeratotic Actinic Keratosis Hyperpigmentation Isotretinoin Late Stage Products Mild/Moderate Onychomycosis Pharmaceutical Dermatology Recurrent Herpes Labialis Severe Nodular Acne

Home Page: www.cipherpharma.com

CPH Technical Analysis

209 Oak Park Boulevard
Oakville, ON L6H 0M2
Canada
Phone: 905 602 5840


Officers

Name Title
Mr. Craig J. Mull Interim CEO & Chairman
Dr. Diane Gajewczyk VP of Scientific & Medical Affairs
Mr. Bryan Jacobs Chief Financial Officer
Mr. Emilio Presti Director of Sales, Marketing & Hospital Bus.
Chuoru Li Corp. Controller
David Miller Director of Fin.

Exchange: TO

Country: CA

Currency: Canadian Dollar (C$)

Forward PE: 8.9847
Trailing PE: 7.7813
Price-to-Book MRQ: 1.5675
Price-to-Sales TTM: 4.4047
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks